Treatment Consultation and Case Review Support in Japan

Cancer Treatment Options That May Be Considered in Japan

From heavy-ion and proton therapy to immune-cell therapies and personalized vaccines, we help organize medical records, arrange second opinions, and let Japanese physicians evaluate whether treatment in Japan is appropriate.

Japan Advanced Cancer Therapies in One Minute

Which therapies, who they are intended for, how a second opinion is arranged

Which cancer therapies does Medical Supporter introduce?
Treatment categories that may be discussed in Japan include heavy-ion and proton therapy, photoimmunotherapy, immune-cell therapy, vaccine-related consultation, gene-related therapy consultation, regenerative medicine, and ECCT. Suitability, acceptance, and actual treatment plans must be determined by physicians based on records.
Who are these therapies intended for?
Typically patients who have reached limits with standard care, are seeking a second opinion, or want to combine advanced immune or particle therapies with their current plan. Suitability is determined by the Japanese physician based on the case; this platform only coordinates and refers.
How do I arrange a second opinion with a Japanese physician?
During the online consultation, share your records and imaging. We translate and forward them to the Japanese physician. A written second opinion is typically returned in 5–10 business days. Video consultations are scheduled separately, led by the Japanese doctor with our interpretation support.
Showing all 11 treatment categories
Heavy Ion / Proton Therapy
Particle / Local Therapy

Heavy Ion / Proton Therapy

Heavy Ion / Proton Therapy

QST Hospital (World's first HIMAC, 15,024 treatments)SAGA HIMAT (Kyushu International Heavy-Ion Cancer Center)MediProton International Proton Therapy Center (Kagoshima)

Particle therapy uses carbon ions or protons and the Bragg Peak effect to concentrate radiation dose at tumor depth. Institutions such as QST, SAGA HIMAT, and MediProton evaluate suitability based on cancer type, stage, imaging, and prior treatment records; fractions, risks, and expected benefits must be explained by radiation oncologists.

Carbon-ion and proton therapy evaluation
Bragg Peak dose-concentration planning
QST respiratory gating, 3D scanning, and rotational irradiation options
Fractions and risks explained case by case by the hospital
Learn Full DetailsConsult About This Treatment
Near-Infrared Photoimmunotherapy / ICG Liposome
Particle / Local Therapy

Near-Infrared Photoimmunotherapy / ICG Liposome

Near-Infrared Photo Immuno Therapy (PIT) / ICG Liposome

TGC Tokyo Cancer Clinic (Medical Supporter exclusive partner)Tokyo Cancer Clinic (ABeVax + PIT)Saisei Mirai Group (Photodynamic + Sonodynamic)

Summarizes public consultation information on photoimmunotherapy, photodynamic, and sonodynamic options from TGC Tokyo Cancer Clinic, Tokyo Cancer Clinic, and Saisei Mirai Group. Irradiation method, depth, fees, risks, and current availability require case-by-case confirmation.

PIT / ICG Liposome availability requires confirmation
External and intravascular irradiation conditions must be checked
ERP / photosensitizer information is technical background
Do not frame as immune-memory or efficacy guarantees
Learn Full DetailsConsult About This Treatment
ECCT Electric Field Adjuvant Therapy
Particle / Local Therapy

ECCT Electric Field Adjuvant Therapy

Electro-Capacitive Cancer Therapy

Saisei Mirai Group

Summarizes consultation information on ECCT low-frequency electric-field adjunctive therapy. Eligibility, combination with standard care, device use, fees, and risks require case-by-case clinic confirmation.

Physical mechanism requires clinic confirmation
Wearable-device use needs confirmation
Explored in research as an adjunct to chemotherapy
Learn Full DetailsConsult About This Treatment
Six-Cell Combination Immunotherapy
Immune-cell Therapy Consultation

Six-Cell Combination Immunotherapy

Six-Cell Combination Immunotherapy

Dojin ClinicFukuoka Cancer Comprehensive Clinic

A self-pay treatment concept centered on multiple immune-cell types such as NK, dendritic, and T cells. Cell types, blood draw volume, reinfusion schedule, and combination strategy differ by clinic and should be confirmed during consultation.

Combination culture of multiple immune-cell types
Cell types and reinfusion schedule require confirmation
Relationship with standard care should be reviewed
Learn Full DetailsConsult About This Treatment
NK Cell / BAK Therapy + Checkpoint-Drug Consultation
Immune-cell Therapy Consultation

NK Cell / BAK Therapy + Checkpoint-Drug Consultation

NK Cell / BAK + Checkpoint-Drug Consultation

Hiroi Clinic (checkpoint-drug consultation)Akasaka AA Clinic (BAK/integrative medicine requires confirmation)Ikebukuro Clinic (NK + αβT + TRAIL combination)Nagoya Maki Clinic (immune-cell and drug consultation)

Summarizes self-pay consultation information on autologous NK cells, BAK, alpha-beta T cells, dendritic cells, and checkpoint-drug use. Combinations, timing, risk, and follow-up must be confirmed case by case based on cancer type, prior therapy, and patient condition.

Checkpoint-drug use requires physician review
PD-1 / CTLA-4 combinations require safety confirmation
BAK/integrative-medicine information requires current clinic confirmation
NK / alpha-beta T / dendritic-cell combination immunotherapy consultation
Learn Full DetailsConsult About This Treatment
NEO Clinic: Neoantigen Personalized Vaccine
Immune-cell Therapy Consultation

NEO Clinic: Neoantigen Personalized Vaccine

Neoantigen Personalized Vaccine

NEO Clinic TokyoUniversity of Tokyo IMSUT Hospital (research support)

Uses NGS next-generation sequencing and AI prediction models to design a patient-specific vaccine targeting each individual's unique tumor mutation sites — a personalized immune-guidance approach.

NGS and AI analysis may support physician evaluation
Suitability for a personalized approach must be reviewed by a physician
Research background and current availability require case-by-case confirmation
Learn Full DetailsConsult About This Treatment
GcMAF / Hybrid MAT Macrophage Activation Therapy
Immune-cell Therapy Consultation

GcMAF / Hybrid MAT Macrophage Activation Therapy

Macrophage Activation (GcMAF / Hybrid MAT)

Ginza Ichome Clinic (Hybrid MAT plant-derived IAF)Saisei Mirai Group (GcMAF blood-derived + ~1-week preparation)

Ginza Ichome Clinic describes Hybrid MAT as a plant-derived IAF immune-modulator approach combined with supportive oral ARL. Saisei Mirai Group describes GcMAF specimen analysis and blood-derived preparation. These are self-pay treatment materials and require confirmation of current availability, testing flow, fees, and relationship with standard care.

Hybrid MAT and GcMAF details should be confirmed separately
Specimen analysis and preparation flow require review
Self-pay and supportive-care consultation
Learn Full DetailsConsult About This Treatment
Cancer Gene Therapy
Gene-related Therapy Consultation

Cancer Gene Therapy

Cancer Gene Therapy

Ginza PHOENIX Clinic (tumor suppressor injection + gene testing)Ikebukuro Clinic (TRAIL gene + combination immunotherapy)Saisei Mirai Group (JG-1 + lentiviral vector)

Summarizes cancer gene-therapy consultations described in partner-clinic public materials, including Gankyrin-silencing RNA, TRAIL, CDC6shRNA, p16, and JG-1. Current availability, eligibility, fees, risks, and relationship with standard care must be confirmed case by case with the receiving clinic.

Tumor-suppressor injection consultation
Gankyrin-silencing RNA consultation
TRAIL / CDC6 targets require case-by-case confirmation
JG-1 and vector information require case review
Learn Full DetailsConsult About This Treatment
Hasumi Cancer Vaccine (HITV)
Gene-related Therapy Consultation

Hasumi Cancer Vaccine (HITV)

Hasumi Immuno-Tumor Vaccine (HITV)

HASUMI Immuno ClinicTokyo Cancer Clinic

Summarizes Hasumi Clinic public consultation information on Hasumi vaccine, HITV, preHITV, and immune-cell therapy. History, case numbers, and technical background may be cited as clinic material, but not as guarantees of efficacy, low side effects, or eligibility.

Hasumi vaccine history and case counts are background only
Side effects and follow-up require confirmation
Cancer type and patient eligibility require physician review
Learn Full DetailsConsult About This Treatment
Dendritic Cell Vaccine
Precision Medicine

Dendritic Cell Vaccine

Dendritic Cell Vaccine

Tokyo Cancer Clinic (ABeVax 5th gen)Fukuoka Cancer Comprehensive ClinicHASUMI Immuno Clinic

Collects autologous dendritic cells, loads tumor antigens ex vivo, then reinfuses to activate specific CD4+/CD8+ T cell killing. ABeVax 5th generation recognizes up to 8 tumor markers.

Tumor-marker information should be explained by the institution
Immune response and suitability require case-by-case review
Blood draw volume and physical burden must be confirmed by the physician
Learn Full DetailsConsult About This Treatment
Mesenchymal Stem Cell (MSC) Regenerative Medicine
Regenerative Medicine Consultation

Mesenchymal Stem Cell (MSC) Regenerative Medicine

Mesenchymal Stem Cell (MSC) Therapy

REGENE CLINIC (Shinjuku regenerative-medicine consultation)TCB Tokyo Central Cosmetic SurgeryKyushu Regenerative Medicine CenterRISO ClinicOmotesando HELENE Clinic

Summarizes publicly listed mesenchymal stem-cell, PRP, culture-supernatant, and regenerative-medicine consultations at partner clinics. Available care plans, cell source, administration route, eligibility, risks, and fees must be confirmed with each clinic; no disease-treatment or anti-aging outcome is guaranteed.

Stem-cell, PRP, and supernatant consultation
CPC / cell-processing and care plans require confirmation
Eligibility, risks, and fees require case-by-case review
Learn Full DetailsConsult About This Treatment
FAQ

About Japan's Advanced Cancer Treatments

What advanced cancer treatments are available in Japan?

Medical Supporter helps organize information on 10+ treatment categories that may be discussed with Japanese physicians, including particle/local therapy, immune-cell therapy, gene-related therapy consultation, personalized medicine, and regenerative medicine. Suitability, acceptance, and actual treatment plans must be determined by the receiving physician based on medical records.

What is heavy-ion therapy?

Heavy-ion therapy uses carbon ion beams and the Bragg Peak phenomenon to concentrate radiation dose in the planned target area. Suitability, number of sessions, and risks require physician review of imaging, pathology, and overall condition.

How much does cancer treatment in Japan cost?

Treatment costs vary significantly by therapy type and by hospital, and final pricing follows each facility’s formal quote. Once a case is opened, Medical Supporter helps obtain estimates and coordinate Japan travel-readiness documents, accommodation, transport, translation, and accompaniment.

Why do I need Medical Supporter's coordination service?

Many Japanese teaching hospitals and specialty institutions require complete records, translations, clear responsibility boundaries, and defined booking steps for international patients. Medical Supporter helps prepare records, translate documents, request second opinions or referrals, and coordinate travel readiness, accompaniment, and follow-up after the hospital reviews the case.

This page summarizes cancer treatment options and partner medical institutions in Japan. Medical Supporter provides transparent cross-border coordination for record preparation, second opinions and hospital evaluation; indications, expected benefits and risks must be reviewed individually by physicians.